XTL BIopharmaceuticals Limited Company Profile - May 01, 2011

Document Sample
XTL BIopharmaceuticals Limited Company Profile - May 01, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   XTL BIopharmaceuticals Limited
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Israel Shekels

                                  Wright Quality Rating:LCNN                             Key Data

   XTL BIopharmaceuticals Limited. The Group's principal activity is the acquisition,    Ticker:
   development and commercialization of therapeutics for the treatment of neurophatic    XTLB
   pain and, Hepatitis C. The Company is a development stage biotechnology company.
   It does not yet have any product sales and expects to consume cash until products     2008 Sales:
   are commercialised. The Company's shares are traded on the London, New York and
                                                                                         21,166,655
   Tel Aviv Stock Exchange.
                         Stock Chart                                  Officers
                                                                                         Major Industry:
                                                                     Chairman
                                                                                         Drugs, Cosmetics & Health
                                                                     Amit Yonay
                                                                                         Care
                                                               Chief Executive Officer
                                                                     Ron Bentsur         Sub Industry:
                                                                                         Ethical Drug Manufacturers
                                                                  Finance Director
                                                                     Bill Kessler        Country:
                                                                                         Israel

                                                                                         Currency:
                                                                                         Israel Shekels

                                                                                         Fiscal Year Ends:
                                                                                         December

                                                                                         Employees
                                                                                         8
               Stock Price (4/21/2011): 0.64
                 Recent stock performance                                                Exchanges:
                    1 Week        9.8%                                                   OTH
                    4 Weeks      26.4%
                    13 Weeks    -10.9%                                                   Share Type:
                    52 Weeks    123.5%
                                                                                         Ordinary
                       Earnings / Dividends (as of 12/31/2010)
                                              Earnings            Dividends               Market Capitalization:
   Most Recent Qtr                                      -0.01                        0.00 122,119,907
   Last 12 Months                                       -0.04            
				
DOCUMENT INFO
Description: XTL BIopharmaceuticals Limited. The Group's principal activity is the acquisition, development and commercialization of therapeutics for the treatment of neurophatic pain and, Hepatitis C. The Company is a development stage biotechnology company. It does not yet have any product sales and expects to consume cash until products are commercialised. The Company's shares are traded on the London, New York and Tel Aviv Stock Exchange.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.